Drug Profile

Sacituzumab tirumotecan - Klus Pharma/Merck & Co

Alternative Names: MK-2870; sac-TMT; SKB-264

Latest Information Update: 12 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Klus Pharma
Developer Klus Pharma; Merck & Co; Sichuan Kelun-Biotech Biopharmaceutical
Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
Mechanism of Action DNA topoisomerase I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Marketed Non-small cell lung cancer; Triple negative breast cancer
Preregistration HER2 negative breast cancer
Phase III Adenocarcinoma; Cervical cancer; Endometrial cancer
Phase II Biliary cancer; Cancer; Colorectal cancer; Pancreatic cancer; Solid tumours
Phase I/II Bladder cancer; Gastrointestinal cancer; Urogenital cancer

12 Sep 2025 Efficacy and adverse event data from a phase II trial in Non-small cell lung cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology 2025 (ASCO-2025)
19 Aug 2025 Efficacy and adverse event data from the phase II OptiTROP-Lung01 trial in Non-small cell lung cancer released by Sichuan Kelun Pharmaceutical
08 Jul 2025 Sichuan Kelun-Biotech Biopharmaceutical plans a phase III trial for Breast cancer (Metastatic disease, Recurrent, Late-stage disease, Inoperable/unresectable, Second-line therapy or greater) in China(IV) in July 2025 (NCT07071337)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com